Ernexa Therapeutics Inc. (NASDAQ:ERNA) Sees Significant Decline in Short Interest

Ernexa Therapeutics Inc. (NASDAQ:ERNA) was the target of a large drop in short interest in March. As of March 13th, there was short interest totaling 92,109 shares, a drop of 62.7% from the February 26th total of 247,054 shares. Based on an average trading volume of 1,633,921 shares, the short-interest ratio is currently 0.1 days. Approximately 0.3% of the company’s stock are sold short. Approximately 0.3% of the company’s stock are sold short. Based on an average trading volume of 1,633,921 shares, the short-interest ratio is currently 0.1 days.

Institutional Trading of Ernexa Therapeutics

A hedge fund recently bought a new stake in Ernexa Therapeutics stock. Susquehanna International Group LLP bought a new stake in Ernexa Therapeutics Inc. (NASDAQ:ERNA) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned 0.39% of Ernexa Therapeutics at the end of the most recent reporting period. 70.55% of the stock is owned by hedge funds and other institutional investors.

Ernexa Therapeutics Stock Performance

ERNA opened at $0.21 on Wednesday. The firm has a market cap of $6.17 million, a P/E ratio of -0.07 and a beta of 6.58. The firm has a 50-day moving average of $0.59 and a 200 day moving average of $1.07. Ernexa Therapeutics has a fifty-two week low of $0.21 and a fifty-two week high of $4.02.

Ernexa Therapeutics (NASDAQ:ERNA) last announced its quarterly earnings data on Friday, March 13th. The company reported ($0.01) EPS for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Ernexa Therapeutics in a research note on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

About Ernexa Therapeutics

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.